New eye drug could mean fewer shots for wet AMD patients
Disease control
Completed
This study tested a new eye injection called EYP-1901 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to see if EYP-1901 could control the disease as well as the standard treatment aflibercept, but with fewer injections. Th…
Phase: PHASE2 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 07:51 UTC